Recent Results of the ELOQUENT-3 Study Relapsed and refractory Multiple Myeloma: Doubling of progression-free Survival under the Elotuzumab Triplet

被引：0
|
作者：
Thaesler, Elke
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷 / 12期
关键词：
PLUS POMALIDOMIDE; DEXAMETHASONE; CS1;
D O I：
10.1159/000504821
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：692 / 693
页数：2
相关论文
共 50 条
  • [1] Refractory Multiple Myeloma Doubling progression-free Survival for Elotuzumab in Combination with Pomalidomide and Dexamethasone in the ELOQUENT-3 Study
    Freyer, Martina
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (7-8) : 390 - 391
  • [2] ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis
    Raab, Marc-Steffen
    Dimopoulos, Meletios
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    Leblanc, Richard
    Suzuki, Kenshi
    Richardson, Paul G.
    Mckiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174
  • [3] ELOQUENT-3 study: elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma - final analysis of overall survival (OS)
    Raab, M. S.
    Dimopoulos, M.
    Dytfeld, D.
    Grosicki, S.
    Moreau, P.
    Takezako, N.
    Hori, M.
    Leleu, X.
    LeBlanc, R.
    Suzuki, K.
    Richardson, P. G.
    Popa McKiver, M.
    Jou, Y. -M.
    Yao, D.
    Das, P.
    San-Miguel, J.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 87 - 87
  • [4] Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Shelat, Suresh G.
    Robbins, Michael
    Rafferty, Brian
    San-Miguel, Jesus
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E164 - E165
  • [5] Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study
    Hori, Mitsuo
    Takezako, Naoki
    Sunami, Kazutaka
    Ito, Shigeki
    Kuroda, Junya
    Popa-McKiver, Mihaela
    Jou, Ying-Ming
    Shelat, Suresh G.
    Miyoshi, Masafumi
    Suzuki, Kenshi
    [J]. BLOOD, 2018, 132
  • [6] Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 568 - +
  • [7] Relative Progression-Free Survival Over Time with Novel Triplet Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma
    Betts, Keith A.
    Chen, Clara
    Zichlin, Miriam L.
    Brun, Alexander
    Signorovitch, James E.
    Makenbaeva, Dinara
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S334 - S335
  • [8] RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Betts, K.
    Chen, C.
    Zichlin, M.
    Brun, A.
    Signorovitch, J.
    Makenbaeva, D.
    [J]. HAEMATOLOGICA, 2017, 102 : 533 - 533
  • [9] Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study
    Weisel, Katja
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Cocks, Kim
    Espensen, Ashlee
    Popa-McKiver, Mihaela
    Chen, Clara
    Cavo, Michele
    [J]. BLOOD, 2018, 132
  • [10] Daratumumab Improves Progression-Free Survival in Relapsed/Refractory Myeloma
    Schuyler, Devon
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 915 - 915
12345